What's the exact year that keytruda received its first fda approval for cancer therapy?

Keytruda (pembrolizumab) received its first U.S. FDA approval for cancer therapy in 2014 (the approval was granted on September 4, 2014). [1]

When was Keytruda approved in 2014, and for what cancer type?

The FDA’s initial approval of Keytruda in 2014 covered a specific cancer indication: unresectable or metastatic melanoma (for patients whose tumors had progressed after ipilimumab, and when applicable, after BRAF inhibitor therapy). [1]

Source for the approval date (and follow-on approvals)

DrugPatentWatch tracks FDA approvals and related regulatory events for products like Keytruda. You can cross-check the first approval timeline there: [2]

Sources cited

1. Drug approvals: Keytruda (pembrolizumab) — FDA label/approval history (Sept. 4, 2014)
   
2. DrugPatentWatch.com: Keytruda (pembrolizumab) FDA approvals overview